证券简称：安杰思 证券代码：688581 杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划 （草案） 杭州安杰思医学科技股份有限公司 二〇二五年四月 声 明 本公司及全体董事、监事保证本激励计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其真实性、准确性、完整性依法承担法律责任。 本公司所有激励对象承诺，若公司因信息披露文件中有虚假记载、误导性陈 述或者重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关 信息披露文件被确认存在虚假记载、误导性陈述或重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 1 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第4号——股权激励信息披露》等其他有关法律、法规、 规范性文件以及《杭州安杰思医学科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。股票 来源为杭州安杰思医学科技股份有限公司（以下简称"安杰思""公司"或"本 公司""上市公司"）从二级市场回购的公司A股普通股 ...

杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划激励对象名单 | 序号 姓名 | 国籍 | 职务 | 获授的限制性 | 占授予限制性股票 | 占公司总股本的比 | | --- | --- | --- | --- | --- | --- | | | | | 股票数量（股） | 总数的比例 | 例 | | 核心管理人员及核心技术（业务）人员 | | | 16,089 | 100% | 0.02% | | （3人） | | | | | | | 合计 | | | 16,089 | 100% | 0.02% | 4、本激励计划中部分合计数与各明细数相加之和在尾数上如有差异，系以上百分比结果四 舍五入所致。 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未 超过公司总股本的1%。公司全部有效期内的激励计划所涉及的标的股票总数累计不超过股权激励 计划提交股东大会审议时公司股本总额的20%。 2、本激励计划涉及的激励对象不包括独立董事、监事、单独或合计持股5%以上的股东或实 际控制人及其配偶、父母、子女。 3、在限制性股票授予前，激励对象因离职或因个人原因自愿放弃获授权益的，由董 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-025 杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划（草案）摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、股权激励计划目的 为了进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动 公司（含子公司）的员工积极性，有效地将股东利益、公司利益和核心团队个人 利益结合在一起，使各方共同关注公司的长远发展，在充分保障股东利益的前提 下，按照收益与贡献对等的原则，公司依据《公司法》《证券法》《管理办法》 《上市规则》《自律监管指南第 4 号》等有关法律、法规和规范性文件以及《公 司章程》的规定，制定本激励计划。 截至本激励计划草案公告日，公司同时正在实施公司 2023 年限制性股票激 励计划。本激励计划与公司 2023 年限制性股票激励计划相互独立，不存在相关 联系。 公司2023年限制性股票激励计划经公司2023年第二次临时股东大会审议通 过，公司分别于 2023 年 9 月 7 日向 69 名首次授予激励对象 ...

目 录 | 一、审计报告……………………………………………………… 第 1—6 页 | | | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 页 | | | （一）合并资产负债表…………………………………………… 第 7 | 页 | | （二）母公司资产负债表………………………………………… 第 8 | 页 | | （三）合并利润表………………………………………………… 第 9 | 页 | | （四）母公司利润表………………………………………………第 10 | 页 | | （五）合并现金流量表……………………………………………第 11 | 页 | | （六）母公司现金流量表…………………………………………第 12 | 页 | | （七）合并所有者权益变动表……………………………………第 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 14 | 页 | | 三、财务报表附注……………………………………………… 第 15—84 | 页 | | 四、附件 ………………………………………………………… 第 85—88 | 页 | | ...

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司全资子公司 通过增资实施股权激励及公司放弃优先认购权 暨关联交易的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思全资子公司通过增资实施股权激励及公司放弃优 先认购权暨关联交易的事项进行了核查，具体情况如下： 一、本次增资概述 （一）本次增资的基本情况 为进一步落实安杰思的发展战略，优化全资子公司杭安医学科技（杭州）有 限公司（以下简称"杭安医学"）的资本结构，同时建立健全杭安医学的长效激 励机制，提升杭安医学的运营及管理效率、可持续发展能力及核心竞争力，吸引 和留住优秀人才，有效地将各方利益结合在一起，实现价值共创、利益共享，促 进员工与杭安医学的共同成长及发展，杭安医学拟通过增资形式引入员工持股平 台杭州鼎亮企业管理合伙企业（有限合伙）（以下简称"杭州鼎亮"）。 本次杭州鼎亮出 ...

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思 2024 年度募集资金存放与使用情况进行了核查， 具体情况如下： 一、募集资金基本情况 二、募集资金管理情况 1 （一）募集资金管理制度情况 为规范公司募集资金管理和使用，保护投资者权益，安杰思按照《中华人民 共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》和《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、 法规和规范性文件的规定，结合公司实际情况，制定了《杭州安杰思医学科技股 份有限公司募集资金管理办法》，对募集资金的存放、使用、项目实施管理、投 资项目的变更及 ...

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 调整募投项目内部投资结构的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思调整募投项目内部投资结构的事项进行了核查， 具体情况如下： 一、募集资金的基本情况 （一）募投项目内部投资结构调整的具体情况 根据安杰思业务发展规划及募投项目的实际进展情况，为提高募集资金使用 效率，确保募投项目建设稳步推进，安杰思经审慎研究，拟对"营销服务网络升 级建设项目"和"微创医疗器械研发中心项目"的内部投资结构进行调整，募投 项目承诺投资总额不变。该等募投项目内部投资结构调整前后具体情况如下： 1、安杰思拟对"营销服务网络升级建设项目"内部投资结构作出如下调整： 经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册 ...

一、募集资金的基本情况 经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册，并经上海证 券交易所同意，安杰思首次向社会公开发行人民币普通股（A 股）股票 1,447.0000 万股，发行价格为每股人民币 125.80 元，募集资金总额为人民币 182,032.60 万 元，扣除发行费用人民币（不含增值税）16,931.32 万元后，实际募集资金净额为 人民币 165,101.28 万元。上述募集资金已于 2023 年 5 月 16 日全部到位，并经天 健会计师事务所（特殊普通合伙）审验，于 2023 年 5 月 17 日出具了《验资报 告》（天健验〔2023〕210 号）。 中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥128,599,967.29, representing a 15.27% increase compared to ¥111,561,373.32 in the same period last year[4]. - Net profit attributable to shareholders was ¥56,248,260.62, up 6.57% from ¥52,781,143.37 year-on-year[4]. - Operating profit for Q1 2025 was ¥66,143,296.06, representing a growth of 8.3% from ¥61,034,409.57 in Q1 2024[18]. - Basic and diluted earnings per share were both ¥0.69, up 6.15% from ¥0.65 in the same period last year[4]. - The total comprehensive income for Q1 2025 was ¥56,329,913.25, compared to ¥52,776,576.47 in Q1 2024, reflecting overall growth[19]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 47.25% to ¥7,531,575.42, down from ¥14,279,053.92 in the previous year[4][7]. - Cash flow from operating activities for Q1 2025 was ¥7,531,575.42, a decrease from ¥14,279,053.92 in Q1 2024[21]. - The company reported a net cash inflow from investment activities of ¥28,565,344.17 in Q1 2025, contrasting with a net outflow of ¥15,131,011.34 in Q1 2024[22]. - The company experienced a net increase in cash and cash equivalents of ¥36,612,548.71 in Q1 2025, reversing a decrease of ¥20,450,446.38 in Q1 2024[22]. - Total cash and cash equivalents at the end of Q1 2025 were ¥1,067,829,933.85, compared to ¥1,934,281,703.88 at the end of Q1 2024[22]. Research and Development - Total R&D investment reached ¥12,992,919.40, an increase of 13.05% compared to ¥11,493,491.83 in the same period last year[5]. - R&D expenditure accounted for 10.10% of operating revenue, a slight decrease from 10.30% in the previous year[5]. - Research and development expenses increased to ¥12,992,919.40 in Q1 2025, up from ¥11,493,491.83 in Q1 2024, indicating a focus on innovation[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,556,661,527.87, reflecting a 0.27% increase from ¥2,549,778,243.93 at the end of the previous year[5]. - The company's current assets totaled RMB 1,903,653,588.44, compared to RMB 1,894,390,045.41 at the end of 2024, reflecting a growth of approximately 0.14%[13]. - The company's total liabilities decreased to RMB 102,564,409.63 from RMB 152,666,866.13, indicating a reduction of approximately 32.8%[15]. - The total equity attributable to shareholders rose to RMB 2,454,097,118.24 from RMB 2,397,111,377.80, marking an increase of about 2.4%[15]. - Accounts payable decreased significantly from RMB 63,746,014.03 to RMB 41,518,370.56, a decline of approximately 34.8%[15]. - The company reported a total inventory of RMB 60,922,431.15, up from RMB 56,377,372.06, which is an increase of about 9.6%[13]. - The company’s long-term assets totaled RMB 653,007,939.43, slightly down from RMB 655,388,198.52, a decrease of about 0.2%[14]. Shareholder Information - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12]. - Non-recurring gains and losses totaled ¥7,586,988.87 after tax, with significant contributions from government subsidies and asset disposals[6]. Return on Equity - The weighted average return on equity decreased slightly to 2.32% from 2.37% year-on-year[4].

Financial Performance - The company's operating revenue for 2024 reached ¥636,634,113.59, representing a 25.14% increase compared to ¥508,748,507.24 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥293,393,685.99, a growth of 35.06% from ¥217,238,584.26 in 2023, driven by increased sales volume[26]. - The net cash flow from operating activities increased by 42.61% to ¥315,795,149.98 in 2024, up from ¥221,447,224.50 in 2023, due to rapid revenue growth[26]. - Basic earnings per share for 2024 were ¥3.6414, a 21.66% increase from ¥2.9932 in 2023[24]. - The company's total assets as of the end of 2024 were ¥2,549,778,243.93, reflecting a 9.38% increase from ¥2,331,074,065.19 at the end of 2023[23]. - The company reported a net profit of ¥95,940,901.10 in Q4 2024, contributing to a total annual net profit growth[28]. - The net profit attributable to shareholders for Q3 2024 was ¥72,999,557.15, indicating consistent quarterly growth[28]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of 13.8 RMB per 10 shares, totaling approximately 111.20 million RMB, which represents 48.46% of the net profit attributable to shareholders for 2024[6]. - The total amount for cash dividends and share repurchases is 142.16 million RMB, accounting for 48.46% of the net profit attributable to shareholders[6]. - The company has implemented a share repurchase program amounting to 30.97 million RMB, excluding transaction costs[6]. Research and Development - Research and development expenses accounted for 9.30% of operating revenue in 2024, up from 8.11% in 2023[24]. - The company launched 27 product design improvement projects and has 19 new products under development, alongside 7 pre-research projects during the reporting period[37]. - The company is advancing multiple R&D pipelines, including reusable flexible endoscopes and AI-driven clinical diagnosis products, with several products expected to enter the registration phase in 2025[39]. - The total R&D expenditure for the year amounted to ¥59,209,169.42, representing a 43.53% increase compared to ¥41,251,410.55 in the previous year[73]. - The increase in R&D investment is primarily attributed to the development of auxiliary treatment robots and flexible endoscope products, along with an increase in R&D personnel[74]. Market Expansion and Strategy - The company plans to continue expanding its global market presence, which has been a key driver of revenue growth[25]. - The international market continues to show high growth, contributing significantly to overall revenue increases[35]. - The company is actively pursuing market expansion through the introduction of innovative medical devices, enhancing its competitive edge in the healthcare sector[74]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[186]. - The company plans to implement a product development and market sales strategy that emphasizes "sales generation, R&D generation, and exploration generation" to enhance its market position[153]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[9]. - The company has not faced any issues with more than half of the board members being unable to guarantee the authenticity and completeness of the annual report[9]. - The company has established a comprehensive information disclosure management system to ensure timely and accurate reporting of significant operational matters[175]. - The company is committed to maintaining high standards of corporate governance, as reflected in the rigorous processes followed by its various committees[198]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, which can be found in the "Management Discussion and Analysis" section[4]. - The company faced risks related to talent retention and potential technology leaks, which could impact its competitive advantage[100][101]. - The company is closely monitoring macroeconomic conditions and adjusting its strategies to mitigate potential impacts from economic fluctuations and policy changes[97]. - The company is facing intensified market competition domestically, with a trend of decreasing procurement prices due to stricter medical insurance cost control[89]. Product Development and Innovation - The company has developed new features for its devices, including detachable and interchangeable clip devices, enhancing operational safety and reducing procedure time[58]. - The company has introduced innovative technologies in the ERCP field, improving the success rate of cannulation with a new coating guidewire technology[58]. - The company is focusing on integrating AI and machine learning into endoscopic procedures to enhance diagnostic accuracy and improve patient outcomes[140]. - The company aims to maintain high R&D investment, particularly in AI clinical diagnosis and minimally invasive treatment technologies, to enhance product competitiveness[162]. Financial Management - The company’s investment activities resulted in a net cash outflow of 1.13 billion yuan, primarily due to the purchase of structured deposits[104]. - Cash and cash equivalents decreased to ¥1,031,231,385.14, representing 40.44% of total assets, down 47.24% from the previous year due to structural deposit purchases[126]. - The company’s trading financial assets increased significantly to ¥671,221,183.18, accounting for 26.32% of total assets, up 714.40% from ¥82,419,132.42 last year[126]. - The company plans to use idle self-owned funds for cash management and increase the amount of temporarily idle raised funds for cash management[192].